All News
Filter News
Found 31 articles
-
Money on the Move: April 14-20
4/21/2021
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week. -
COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More
4/20/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 20, 2021. -
The new financing round was led by RA Capital Management, in tandem with new investors Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another unnamed investor from the health care space.
-
Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19
4/19/2021
Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, announced the completion of a $336 million Series C financing led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor.
-
Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
4/13/2021
Phase 1/2/3 STAMP Trial to be Conducted Globally, Including in Countries with High Rates of SARS-CoV-2 Variants Resistant to Other Monoclonal Antibody Products
-
Adagio Therapeutics to Participate in Cowen 41st Annual Health Care Conference
2/22/2021
Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced that Tillman Gerngross, Ph.D., chief executive officer, and Jane Henderson, chief financial officer, will participate in one-on-one investor meetings during the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021.
-
Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19
2/16/2021
-ADG20 is uniquely engineered to maximize potency, duration of effect, and ease of use in the community setting, and has shown outstanding manufacturability to meet global demand-
-
Adagio Therapeutics Publishes Preclinical Data in Science Demonstrating Best-in-Class Breadth and Potency Against SARS-CoV-2, Including Known Circulating Resistance Variants, and a Range of Pre-Emergent Coronaviruses
1/25/2021
Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today published in vitro and in vivo data in Science on its lead antibody candidate, ADG2, which demonstrated similar or higher potency against SARS-CoV-2 compared to other monoclonal antibodies (mAbs) in clinical development and strong binding to all known SARS-CoV-2 variants.
-
Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat
11/18/2020
Adagio Therapeutics, Inc., today pre-published in vitro and in vivo data demonstrating its lead antibody candidate, ADG2, shows similar or higher potency against SARS-CoV-2 compared to monoclonal antibodies (mAbs) in clinical development, while also uniquely offering broad neutralization against a range of sarbecoviruses that pose a threat to humans.
-
Biopharma Money on the Move: November 4-10
11/11/2020
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs. -
Adagio Therapeutics Raises $80M Series B Round to Further Advance Best-In-Class Antibodies for Coronavirus Treatment and Prevention
11/10/2020
Lead antibody - ADG20 - expected to advance to clinical studies in early 2021, offers potential best-in-class treatment and durable protection against SARS-CoV-2 and future coronaviruses